---
cssClasses: img-max
---
[moc::"[[MOC Oral Cavity]]"]
>[!title]
> Combined analysis of 95-01 and EORTC 22931 [Bernier H&N '05](https://onlinelibrary.wiley.com/doi/full/10.1002/hed.20279):  

>[!intervention] 
> Adj RT [± Chemo]  

# study

[[RTOG 9501 (adjRT ± chemo)]]
[[EORTC 22931 (adjRT ± chemo)]]

# results
- 5y OS 40→ 50%. 
- IR features: N+ without ECE, PNI, close margins.


![[img_22931-9501_inclusion.png#invert|400]]![[img_22931-9501_results.png#invert|400]]

>[!summary] 
> How should we manage operable locally-advanced OC?
> - per the combined analysis of [[EORTC 22931 (adjRT ± chemo)|22931]] and [[RTOG 9501 (adjRT ± chemo)|9501]], with adjuvant RT and concurrent chemo. 
> - This analysis found that, in patients with ENE and/or positive margins, adjuvant chemo provides a 10% benefit in 5y OS. Without these risk factors, though, there was no benefit to concurrent chemo.
>^summary

# notes
- other possible indications
	- multiple positive nodes (3+)
	- close margins (<5mm)
![[06_22931-9501.pdf]]